Table 1.
| Sample Injected | n | normal/bent tail | strong dorsalized class 4/5 or bustled | weak dorsalized class 1/2/3 | mild ventralized | moderate ventralized | severe ventralized | lysed |
|---|---|---|---|---|---|---|---|---|
| StCon-MO | 96 | 100% | 0% | 0% | 0% | 0% | 0% | 0% |
| 5′1-MO (0.1mM) | 69 | 100% | 0% | 0% | 0% | 0% | 0% | 0% |
| Chd-MO (0.026 mM) | 88 | 0% | 0% | 0% | 98% | 2% | 0% | 0% |
| SP-MO (0.5mM) | 43 | 100% | 0% | 0% | 0% | 0% | 0% | 0% |
| 5′1-MO + Chd-MO (0.1 mM/0.026 mM) | 196 | 0% | 0% | 0% | 2% | 31% | 67% | 0% |
| SP-MO + Chd-MO (0.5 mM/0.026 mM) | 56 | 0% | 0% | 0% | 11% | 21% | 68% | 0% |
| Chl RNA (1 ng) | 68 | 0% | 7% | 93% | 0% | 0% | 0% | 0% |
| mCHL2 RNA (1 pg) | 41 | 0% | 19% | 49% | 0% | 0% | 0% | 32% |
| mCHL1-Fc RNA (80 pg) | 28 | 11% | 28% | 50% | 0% | 0% | 0% | 11% |
| 5′1-MO + Chd-MO + Chl RNA | 89 | 0% | 6% | 5% | 39% | 30% | 16% | 4% |
| 5′1-MO + Chd-MO + mCHL2 RNA | 52 | 0% | 14% | 42% | 17% | 4% | 0% | 23% |
| 5′1-MO + Chd-MO + mCHL1-Fc RNA | 26 | 0% | 12% | 27% | 27% | 19% | 4% | 11% |